



MEETING AGENDA


Pharmacy and Therapeutics Committee

Virtual Meeting

October 22, 2025 12:00PM – 5:00PM

Registration: <https://events.teams.microsoft.com/event/c8a6b88f-9933-4321-9db3-6849fa05a261@eacd16bf-dc0e-44db-8e3f-be370c71feca>

TIME	TOPIC/PRESENTER
12:00 PM	Welcome & Introductions: Suzanne Berman, RPH, AHCCCS Pharmacy Director
12:10 PM	Minutes Review & Vote - P&T May 21, 2025: Suzanne Berman
12:15 PM	<p>Non-Supplemental Rebate Drug Class Review: Clinical review by Hind Douiki, PharmD, Prime Therapeutics</p> <ol style="list-style-type: none"> 1. Analgesics Narcotics, Short Acting <ol style="list-style-type: none"> a. Public Testimony: None 2. Angiotensin Modulators <ol style="list-style-type: none"> a. Public Testimony: None 3. Angiotensin Modulator Combinations <ol style="list-style-type: none"> a. Public Testimony: None 4. Anticonvulsants <ol style="list-style-type: none"> a. Public Testimony: None 5. Antifungals, Oral <ol style="list-style-type: none"> a. Public Testimony: None 6. Antifungals, Topical <ol style="list-style-type: none"> a. Public Testimony: None 7. Antihistamines, Minimally Sedating <ol style="list-style-type: none"> a. Public Testimony: None 8. Antimigraine, Triptans <ol style="list-style-type: none"> a. Public Testimony – Oral: <ol style="list-style-type: none"> i. Asma Sikder 9. Beta Blockers <ol style="list-style-type: none"> a. Public Testimony: None 10. BPH Treatments <ol style="list-style-type: none"> a. Public Testimony: None 11. Calcium Channel Blockers <ol style="list-style-type: none"> a. Public Testimony: None 12. Contraceptives, Oral <ol style="list-style-type: none"> a. Public Testimony: None 13. Contraceptives, Other <ol style="list-style-type: none"> a. Public Testimony: None 14. Hypoglycemics, DPP4s <ol style="list-style-type: none"> a. Public Testimony: None 15. Intranasal Rhinitis Agents <ol style="list-style-type: none"> a. Public Testimony: None



MEETING AGENDA

	<p>16. Lipotropics, Statins a. Public Testimony: None</p> <p>17. Lipotropics, Other a. Public Testimony: None</p> <p>18. Ophthalmics, Glaucoma Agents a. Public Testimony: None</p> <p>19. Phosphate Binders a. Public Testimony: None</p> <p>20. Proton Pump Inhibitors a. Public Testimony: None</p>
2:45 PM	<p>New Drug Reviews: Hind Douiki</p> <p>1. Journavx a. Public Testimony – Oral: i. Jessica Jay</p> <p>2. Ryzneuta</p> <p>3. Orlynvah</p>
3:00 PM	Break - 15 Minutes
3:15 PM	Executive Session: Amber Small, PharmD, Prime Therapeutics
4:45 PM	Public Therapeutic Class Votes: Hind Douiki
5:00 PM	<p>Meeting Adjournment 2026 Meeting Dates: Jan 13, May 19, October 21</p>